Renaxen 5 mg (Axitinib): Uses, Dose, Price & Safety

What Is Renaxen 5 mg?

Renaxen 5 mg is an oral tablet containing Axitinib INN 5 mg. It is listed as a product of Everest Pharmaceuticals Ltd. Axitinib is a targeted cancer medicine that inhibits vascular endothelial growth factor receptors (VEGFRs).

Axitinib is used in the treatment of advanced renal cell carcinoma (RCC) under approved treatment regimens. It may be prescribed alone after previous systemic therapy or in combination with certain immunotherapy medicines for first-line treatment of advanced RCC.

The usual starting dose of Axitinib is 5 mg twice daily, although the treating oncologist may adjust the dose based on tolerability, adverse effects, drug interactions, and treatment response.

Renaxen 5 mg is a prescription medicine and should only be used under appropriate medical supervision.

What Is Axitinib 5 mg Used For?

Axitinib 5 mg is primarily used to treat advanced renal cell carcinoma, a type of kidney cancer.

Depending on the treatment setting and applicable regulatory approval, Axitinib may be used:

• Alone after failure of one prior systemic treatment.
• With pembrolizumab as first-line therapy for advanced RCC.
• With avelumab as first-line therapy for advanced RCC.

The appropriate treatment depends on the patient’s cancer type, disease stage, previous treatments, general health, and other clinical factors.

How Does Renaxen 5 mg Work?

Renaxen 5 mg works through its active ingredient, Axitinib.

Axitinib selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3. These receptors are involved in signaling pathways that help tumors develop new blood vessels.

This process is called angiogenesis.

Tumors need a blood supply to receive oxygen and nutrients. VEGF signaling can help support the formation of new blood vessels around a tumor.

Axitinib blocks this signaling pathway.

In simple terms:

Axitinib → VEGFR inhibition → reduced VEGF signaling → reduced tumor blood-vessel formation.

This is why Axitinib is classified as an antiangiogenic targeted therapy and a VEGFR tyrosine kinase inhibitor.

Does Axitinib Kill Cancer Cells Directly?

Axitinib does not work in the same way as traditional cytotoxic chemotherapy.

Its primary action is to inhibit VEGFR signaling and reduce the formation and maintenance of blood vessels that support tumor growth.

The effectiveness of treatment is assessed through clinical outcomes such as:

• Tumor response
• Progression-free survival
• Overall survival
• Disease progression
• Tolerability

The response varies from patient to patient.

Renaxen 5 mg Quick Facts

 

Product Detail	Information
Brand/Product	Renaxen 5 mg
Active Ingredient	Axitinib INN
Strength	5 mg
Dosage Form	Oral tablet
Drug Class	VEGFR tyrosine kinase inhibitor
Main Targets	VEGFR-1, VEGFR-2, VEGFR-3
Main Established Use	Advanced renal cell carcinoma
Manufacturer	Everest Pharmaceuticals Ltd.
Pack Size	60 tablets
Listed Shelf Life	24 months
Prescription Status	Prescription medicine
Typical Starting Dose	5 mg twice daily
Food Requirement	With or without food

The supplied product information identifies Renaxen 5 mg as an Axitinib INN product manufactured by Everest Pharmaceuticals Ltd.

Renaxen 5 mg Supplier and Other Details

The supplier/exporter information associated with this product identifies Emergency Drug as the international supplier/exporter.

Because Renaxen 5 mg is a prescription cancer medicine, patients should confirm prescription, import, and regulatory requirements before ordering internationally.

FDA-Recognized Uses of Axitinib

Axitinib has an established role in the treatment of advanced renal cell carcinoma.

US prescribing information includes Axitinib:

• In combination with pembrolizumab for first-line treatment of advanced RCC.
• In combination with avelumab for first-line treatment of advanced RCC.
• As a single agent for advanced RCC after failure of one prior systemic therapy.

The regulatory status of a specific generic product, including Renaxen 5 mg, can differ between countries.

Therefore, approval of Axitinib in one jurisdiction does not automatically mean that every Axitinib product has the same regulatory status in every country.

Renaxen 5 mg for Advanced Renal Cell Carcinoma

Renal cell carcinoma is the most common type of kidney cancer in adults.

Advanced RCC may occur when the cancer has spread beyond the kidney or cannot be completely removed with surgery.

Treatment decisions are individualized. An oncologist may consider:

• RCC subtype
• Disease stage
• Previous cancer treatment
• IMDC risk group
• General health
• Kidney function
• Liver function
• Blood pressure
• Cardiovascular risk
• Other medicines
• Previous immunotherapy or targeted therapy

Axitinib is one of several targeted medicines used in advanced RCC.

Renaxen 5 mg Dose and Administration

The usual starting dose of Axitinib as a single agent is:

5 mg orally twice daily.

The doses are generally taken approximately 12 hours apart.

For example, a patient may be instructed to take Axitinib at:

• 8:00 AM
• 8:00 PM

The exact schedule should follow the prescribing physician’s instructions.

Axitinib can be taken with or without food.

The tablet should be swallowed whole with water. Patients should not crush, chew, or alter the tablet unless specifically instructed by a healthcare professional.

 

What If You Miss a Renaxen 5 mg Dose?

If a dose is missed, patients should follow the instructions provided by their healthcare professional or the product information.

Patients should not take a double dose to compensate for a missed dose unless specifically instructed by their healthcare provider.

If vomiting occurs after taking Axitinib, an extra dose should not automatically be taken. The next dose should generally be taken at the scheduled time unless the treating team gives different instructions.

Renaxen 5 mg Dose Adjustments

The standard 5 mg twice-daily dose is a starting dose, not necessarily the dose that every patient will continue throughout treatment.

Doctors may interrupt or reduce treatment if adverse effects occur.

In selected patients who tolerate treatment well, the Axitinib dose may be increased to:

• 7 mg twice daily
• Then, when appropriate, 10 mg twice daily

Dose increases and reductions require medical supervision.

Never increase, decrease, stop, or restart Renaxen 5 mg on your own.

The appropriate dose is the dose that provides the best balance between treatment effectiveness and tolerability.

Renaxen 5 mg Side Effects

Like other cancer medicines, Axitinib can cause adverse effects.

Common side effects include:

• High blood pressure
• Diarrhea
• Fatigue
• Decreased appetite
• Nausea
• Hoarseness or dysphonia
• Hand-foot syndrome
• Weight loss
• Vomiting
• Weakness
• Constipation

Not every patient experiences these effects.

The severity can also vary during treatment.

Serious Renaxen 5 mg Warnings and Precautions

 

Axitinib can cause serious adverse reactions.

 

Important risks include:

Hypertension

Severe hypertension and hypertensive crisis have been reported.

 

Regular blood-pressure monitoring is important during treatment.

 

Arterial and Venous Thromboembolism

 

Axitinib has been associated with arterial and venous thromboembolic events.

 

Patients with existing cardiovascular or clotting risk factors may require additional clinical assessment.

Hemorrhage

Serious and sometimes fatal bleeding has been reported.

 

Patients should report unusual or heavy bleeding promptly.

Cardiac Failure

Heart failure has been reported during Axitinib treatment.

Symptoms that require medical assessment may include:

• New or worsening shortness of breath
• Swelling of the legs
• Unusual fatigue
• Rapid or unexplained weight gain
• Gastrointestinal Perforation and Fistula

 

Rare but serious gastrointestinal complications can occur.

Urgent assessment is needed for symptoms such as severe abdominal pain, persistent vomiting, fever, or other signs of an acute abdominal problem.

Thyroid Dysfunction

Hypothyroidism may occur during Axitinib treatment.

Thyroid function should be assessed before treatment and periodically during therapy.

 

Proteinuria

Axitinib can cause protein to appear in the urine.

Urine protein should be assessed before and during treatment as recommended by the treating physician.

Liver Toxicity

Changes in liver enzymes can occur.

Liver function tests, including ALT, AST, and bilirubin, may be monitored during treatment.

More frequent monitoring may be required when Axitinib is used with pembrolizumab or avelumab.

Impaired Wound Healing

Axitinib may interfere with wound healing.

The prescribing information recommends withholding Axitinib before planned surgery and avoiding treatment after major surgery until adequate wound healing has occurred.

Patients should always tell their surgeon and oncology team that they are taking Axitinib before undergoing a planned procedure.

When Should You Contact a Doctor?

Seek urgent medical attention if serious symptoms occur, including:

• Severe chest pain
• Sudden shortness of breath
• Fainting
• Severe or unusual bleeding
• Black or bloody stools
• Severe abdominal pain
• Severe or uncontrolled blood pressure
• Sudden weakness
• Difficulty speaking
• Severe headache with neurological symptoms
• Signs of a serious allergic reaction

Do not wait for the next routine oncology appointment if symptoms suggest a potentially serious complication.

Renaxen 5 mg Drug Interactions

Axitinib is metabolized mainly through the CYP3A4/5 enzyme pathway.

Medicines that strongly inhibit CYP3A4/5 may increase Axitinib exposure.

Strong CYP3A4/5 inducers may reduce Axitinib exposure and potentially reduce its effectiveness.

The prescribing information recommends avoiding strong CYP3A4/5 inhibitors and inducers when possible.

If a strong inhibitor cannot be avoided, the Axitinib dose may require adjustment.

Medicines That Require Special Attention

Tell your doctor or pharmacist about every medicine and supplement you use, including:

• Antibiotics
• Antifungal medicines
• HIV medicines
• Antiseizure medicines
• Anticoagulants
• Blood-pressure medicines
• Corticosteroids
• Other cancer medicines
• Vitamins
• Herbal supplements
• Over-the-counter medicines

Grapefruit

Grapefruit and grapefruit juice may increase Axitinib exposure and should be avoided according to Axitinib product information.

Do not assume that an OTC medicine, vitamin, or herbal product is safe to combine with cancer treatment.

Monitoring During Renaxen 5 mg Treatment

Monitoring is an important part of Axitinib therapy.

What May Be Monitored	Why It Matters
Blood pressure	Detect hypertension
Urine protein	Monitor for proteinuria
Liver enzymes	Detect liver toxicity
Bilirubin	Assess liver function
Thyroid function	Detect thyroid dysfunction
Weight and appetite	Monitor nutritional effects
Treatment symptoms	Identify adverse reactions
Cardiac symptoms	Assess possible heart failure
Blood tests	Monitor overall treatment safety
Imaging	Assess tumor response

The exact monitoring schedule depends on the patient’s condition, treatment combination, and oncology team’s recommendations.

Renaxen 5 mg vs Axinix 5 mg

Patients searching for Axitinib products may also come across Axinix 5 mg.

Axinix 5 mg contains Axitinib 5 mg and is listed as a product of Beacon Pharmaceuticals.

Renaxen 5 mg is listed as containing Axitinib INN 5 mg and is manufactured by Everest Pharmaceuticals Ltd.

Feature	Renaxen 5 mg	Axinix 5 mg
Active Ingredient	Axitinib INN	Axitinib
Strength	5 mg	5 mg
Drug Class	VEGFR tyrosine kinase inhibitor	VEGFR tyrosine kinase inhibitor
Manufacturer	Everest Pharmaceuticals Ltd.	Beacon Pharmaceuticals
Listed Pack	60 tablets	60 tablets
Main Established Use	Advanced RCC	Advanced RCC
Typical Starting Dose	5 mg twice daily	5 mg twice daily
Regulatory Status	Depends on destination	Depends on destination

Both products contain the same active ingredient and strength.

However, patients should not automatically switch between products without confirmation from a physician or pharmacist. Product registration, manufacturing details, packaging, and regulatory requirements can vary by market.

Renaxen 5 mg Generic vs Inlyta

Inlyta is the original branded Axitinib product marketed by Pfizer.

Renaxen 5 mg is listed as a generic Axitinib product manufactured by Everest Pharmaceuticals Ltd.

Both contain Axitinib as the active pharmaceutical ingredient, but they are different commercial products.

When considering a generic medicine, patients should verify:

• Active ingredient
• Strength
• Manufacturer
• Product registration
• Packaging
• Batch details
• Expiry date
• Supplier credentials
• Prescription requirements
• Import requirements

Generic pricing can be substantially lower than branded pricing. However, price alone does not establish product quality.

Why Can Generic Axitinib Cost Less?

Generic medicines can cost less than originator products because manufacturers do not need to repeat the same level of original drug-discovery and development investment associated with an innovative medicine.

The final price may also vary because of:

• Manufacturing costs
• Local regulations
• Distribution
• Market size
• Taxes
• Shipping
• Currency exchange rates
• Supplier margins

Patients should evaluate quality and regulatory compliance rather than choosing a medicine solely because it is cheaper.

Axitinib vs Other VEGFR Inhibitors

Axitinib belongs to the VEGFR tyrosine kinase inhibitor family.

Other targeted medicines used in renal cell carcinoma include:

• Sunitinib
• Pazopanib
• Sorafenib
• Cabozantinib
• Lenvatinib
• Tivozanib

⚠️Caveat: These medicines are not identical.

They differ in:

• Molecular targets
• Approved indications
• Treatment combinations
• Dosing
• Drug interactions
• Adverse effects
• Monitoring requirements

There is no single VEGFR inhibitor that is automatically the best choice for every patient.

Selected RCC Targeted Therapy Comparison

Medicine	Main Pathway	Common RCC Role	Important Considerations
Axitinib	VEGFR-1/2/3	Advanced RCC and approved combinations	Hypertension, diarrhea, fatigue
Sunitinib	VEGFR, PDGFR, KIT and others	RCC	Fatigue, hand-foot syndrome, hypertension
Pazopanib	VEGFR, PDGFR, FGFR and others	RCC	Liver monitoring
Cabozantinib	VEGFR, MET, AXL and others	RCC	Diarrhea, fatigue, hand-foot syndrome
Lenvatinib	VEGFR, FGFR and others	RCC combinations	Hypertension, diarrhea, renal/hepatic effects
Tivozanib	VEGFR	RCC	Hypertension and fatigue

Treatment selection should be made by an oncology team based on the patient’s disease and previous treatment.

Clinical Evidence for Axitinib

Axitinib has been evaluated in several important clinical trials involving advanced RCC.

Clinical evidence helps distinguish an established cancer treatment from an untested product.

AXIS Trial

The phase III AXIS trial compared Axitinib with sorafenib in patients with advanced RCC who had received previous systemic treatment.

The study included 723 patients.

Median investigator-assessed progression-free survival was:

• 8.3 months with Axitinib
• 5.7 months with sorafenib

The hazard ratio for progression or death was 0.656, favoring Axitinib.

Median overall survival was:

• 20.1 months with Axitinib
• 19.2 months with sorafenib

The difference in overall survival was not statistically significant.

Therefore, the AXIS trial demonstrated a progression-free survival advantage but did not establish a statistically significant overall-survival advantage.

First-Line Axitinib vs Sorafenib

A separate phase III study evaluated Axitinib and sorafenib in previously untreated metastatic RCC.

Median progression-free survival was:

• 10.1 months with Axitinib
• 6.5 months with sorafenib

However, the PFS difference did not reach statistical significance.

The objective response rate was higher with Axitinib:

• 32% with Axitinib
• 15% with sorafenib

These findings show why Axitinib should not simply be described as “better than every other RCC medicine.”

Treatment selection depends on the clinical setting.

Pembrolizumab Plus Axitinib

The KEYNOTE-426 trial evaluated pembrolizumab plus Axitinib against sunitinib in previously untreated advanced RCC.

The combination demonstrated improvements in progression-free survival and overall survival.

At approximately 30.6 months of follow-up:

Median PFS: 15.4 months with pembrolizumab plus Axitinib vs 11.1 months with sunitinib

• Overall survival hazard ratio: 0.68
• PFS hazard ratio: 0.71

The findings supported pembrolizumab plus Axitinib as an important first-line treatment option for advanced RCC.

However, clinical trial outcomes cannot predict exactly how an individual patient will respond.

Avelumab Plus Axitinib

The JAVELIN Renal 101 trial evaluated avelumab plus Axitinib against sunitinib in previously untreated advanced RCC.

The combination demonstrated improved progression-free survival.

In an updated analysis, median PFS in the overall population was:

• 13.3 months with avelumab plus Axitinib
• 8.0 months with sunitinib

Longer-term analysis did not demonstrate a statistically significant overall-survival difference in the final analysis, although median overall survival remained numerically longer with the combination.

This illustrates why medical information should report both benefits and limitations of clinical evidence.

Renaxen 5 mg Price

The price of Renaxen 5 mg can vary considerably.

Factors that can affect the final cost include:

• Destination country
• Quantity ordered
• Supplier pricing
• Shipping method
• Shipping charges
• Currency exchange rates
• Import requirements
• Customs procedures
• Required documentation

For international orders, a quotation may provide more accurate information than an old public price.

Patients should confirm the current:

• Product price
• Availability
• Shipping cost
• Delivery conditions
• Documentation requirements

before placing an order.

How to Buy Renaxen 5 mg Safely

Renaxen 5 mg is a prescription cancer medicine.

A safer purchasing process includes:

• Obtain a valid prescription from your treating physician.
• Confirm that Axitinib is part of your treatment plan.
• Verify the strength and pack size.
• Confirm the manufacturer’s name.
• Check packaging and expiry information.
• Request batch or product verification when available.
• Confirm the medicine’s regulatory status in your destination country.
• Check local import requirements.
• Use a reputable pharmaceutical supplier.
• Keep the medicine in its original packaging.

Do not purchase cancer medicines from unverified sellers simply because they advertise unusually low prices.

Emergency Drug and International Supply

The supplier information provided for this page identifies Emergency Drug as the exporter/supplier of Renaxen 5 mg.

Emergency Drug states that it supplies generic medicines internationally and works with manufacturers including Everest Pharmaceuticals.

Published delivery information indicates that international delivery may take approximately 5 to 20 days, depending on destination and shipping conditions.

Delivery times are estimates and may change because of customs, courier conditions, documentation, holidays, and destination-country regulations.

Before ordering, patients should confirm that importing Axitinib is permitted in their country.

Renaxen 5 mg Export Destinations

The supplied product brief identifies the following target markets:

• Saudi Arabia
• United Arab Emirates
• Qatar
• Kuwait
• Bahrain
• Oman
• Yemen
• Jordan
• Lebanon
• Syria
• Egypt
• Turkey
• Australia
• New Zealand

Pharmaceutical import regulations differ between countries.

A medicine that can be legally supplied in one country may require additional documentation, authorization, or other conditions in another.

Patients should verify local requirements before ordering.

How to Request a Renaxen 5 mg Quote

A prescription-medicine quotation request should normally include:

• Destination country
• Required strength
• Quantity
• Prescription status
• Preferred shipping method
• Delivery requirements

The supplier can then confirm current availability, pricing, shipping charges, and documentation requirements.

Because pharmaceutical prices and shipping costs can change, patients should rely on a current quotation rather than an outdated online price.

Patient Reviews and Real-World Experience

Patient reviews can provide insight into individual treatment experiences, but they should not replace clinical evidence.

Online review platforms contain limited feedback about branded Axitinib products. A small number of user reviews cannot be considered representative of the experience of all patients.

Online communities may also contain personal reports about Axitinib treatment, including experiences involving diarrhea, hand-foot symptoms, taste changes, fatigue, and other adverse effects.

These reports are individual experiences rather than controlled clinical evidence.

What Can Patients Learn From Reviews?

Patient experiences may help patients prepare questions for their healthcare team, such as:

• How should diarrhea be managed?
• When should I contact my doctor?
• How often should I monitor blood pressure?
• How can hand-foot symptoms be managed?
• Which medicines or foods should I avoid?
• What symptoms require emergency medical attention?

One person’s treatment experience cannot predict another person’s response.

Practical Tips for Taking Renaxen 5 mg

Monitor Blood Pressure

Keep a record of blood-pressure readings if your healthcare team recommends home monitoring.

Bring the record to oncology appointments.

Maintain an Updated Medicine List

Include:

• Prescription medicines
• OTC medicines
• Vitamins
• Minerals
• Herbal products
• Other cancer treatments

Protect Your Hands and Feet

Report redness, burning, swelling, pain, or peeling early.

Watch for Dehydration

Diarrhea and vomiting can cause fluid loss.

Contact your healthcare team if symptoms become significant.

Tell Your Surgeon

Axitinib can affect wound healing.

Always tell your surgeon and other healthcare professionals that you are taking Axitinib before a planned procedure.

Do Not Change Your Dose

Dose changes should only be made by the treating oncology team.

Take Doses Consistently

Try to take twice-daily doses approximately 12 hours apart, according to your prescription.

Pregnancy and Breastfeeding

Axitinib can cause fetal harm.

Patients who can become pregnant should discuss appropriate contraception with their healthcare professional before and during treatment.

The prescribing information advises against breastfeeding during Axitinib treatment.

The appropriate duration of contraception after treatment should be confirmed with the treating clinician and based on the current prescribing information applicable to the medicine.

Renaxen 5 mg Storage

Follow the storage instructions printed on the manufacturer’s packaging.

The supplied Renaxen product information states:

• Store below 30°C.
• Protect from moisture.
• Protect from direct sunlight.
• Keep the medicine in its original packaging.
• Keep out of reach of children.

Do not use tablets that appear damaged, discolored, or otherwise abnormal without consulting a pharmacist or healthcare professional.

Key Takeaways About Renaxen 5 mg

• Renaxen 5 mg contains Axitinib INN 5 mg.
• Axitinib is a targeted VEGFR tyrosine kinase inhibitor.
• Its principal targets are VEGFR-1, VEGFR-2, and VEGFR-3.
• Its established clinical role includes treatment of advanced renal cell carcinoma.
• The usual starting dose is 5 mg twice daily.
• Axitinib can be taken with or without food.
• Dose adjustments may be required because of adverse effects or other clinical factors.
• Blood pressure, liver function, thyroid function, urine protein, and treatment-related symptoms may require monitoring.
• Important risks include hypertension, bleeding, thromboembolic events, cardiac failure, gastrointestinal complications, impaired wound healing, proteinuria, liver toxicity, and thyroid dysfunction.
• Clinical evidence for Axitinib includes major studies such as AXIS, KEYNOTE-426, and JAVELIN Renal 101.
• Renaxen 5 mg should only be used with appropriate medical supervision and according to applicable local prescribing and regulatory requirements.

Conclusion: Is Renaxen 5 mg Right for You?

Renaxen 5 mg contains Axitinib, a targeted cancer medicine used for advanced renal cell carcinoma. It works by blocking VEGFR signaling and reducing blood vessel growth that supports tumors.

It is not for self-treatment. Your oncologist will determine the appropriate dose based on your cancer, previous treatment, health condition, other medicines, and treatment response.

If ordering internationally, verify the product details, prescription requirements, import rules, availability, and total shipping cost before purchase.

Product Trust Statement

• Product: Renaxen 5 mg
• Active Ingredient: Axitinib INN 5 mg
• Manufacturer: Everest Pharmaceuticals Ltd.
• Pack Size: 60 tablets
• Supplier/Exporter: Emergency Drug
• Prescription Status: Required

Product price, availability, packaging, registration, and shipping terms may change. Confirm the latest details before ordering.

Frequently Asked Questions About Renaxen 5 mg

1. What is Renaxen 5 mg used for?

Ans: Renaxen 5 mg contains Axitinib INN 5 mg, a VEGFR tyrosine kinase inhibitor used in advanced renal cell carcinoma. Depending on the approved treatment setting, Axitinib may be used alone after previous systemic therapy or in combination with immunotherapy for first-line advanced RCC.

2. Is Renaxen 5 mg the same as Axitinib 5 mg?

Ans: Renaxen 5 mg is listed as a product containing Axitinib INN 5 mg. Axitinib is the active ingredient. Whether two specific products can be substituted should be confirmed according to local regulatory requirements and the prescriber’s instructions.

3. What is the usual Axitinib 5 mg dose?

Ans: The usual starting dose is 5 mg twice daily, taken approximately 12 hours apart. Axitinib can be taken with or without food. Doctors may adjust the dose based on tolerability, adverse effects, drug interactions, and other clinical factors.

4. Is Axinix 5 mg an alternative to Renaxen 5 mg?

Ans: Axinix 5 mg is another product containing Axitinib 5 mg and is listed by Beacon Pharmaceuticals. Renaxen 5 mg is listed by Everest Pharmaceuticals Ltd. Although both contain Axitinib, patients should confirm product suitability, regulatory status, and interchangeability with their physician or pharmacist before switching.

5.  How much does Renaxen 5 mg cost?

Ans: The price depends on the supplier, destination country, quantity, shipping method, currency, and import requirements. International buyers should request a current quotation rather than relying on an outdated online price.